The prevalence and incidence of neurocognitive impairment in the HAART era

Objectives:HAART suppresses HIV viral replication and restores immune function. The effects of HAART on neurological disease are less well understood. The aim of this study was to assess the prevalence and incidence of neurocognitive impairment in individuals who initiated HAART as part of an AIDS clinical trial. Design:A prospective cohort study of HIV-positive patients enrolled in randomized antiretroviral trials, the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) study. Methods:We examined the association between baseline and demographic characteristics and neurocognitive impairment among 1160 subjects enrolled in the ALLRT study. Results:A history of immunosuppression (nadir CD4 cell count < 200 cells/μl) was associated with an increase in prevalent neurocognitive impairment. There were no significant virological and immunological predictors of incident neurocognitive impairment. Current immune status (low CD4 cell count) was associated with sustained prevalent impairment. Conclusion:The association of previous advanced immunosuppression with prevalent and sustained impairment suggests that there is a non-reversible component of neural injury that tracks with a history of disease progression. The association of sustained impairment with worse current immune status (low CD4 cell count) suggests that restoring immunocompetence increases the likelihood of neurocognitive recovery. Finally, the lack of association between incident neurocognitive impairment and virological and immunological indicators implies that neural injury continues in some patients regardless of the success of antiretroviral therapy on these laboratory measures.

[1]  J. McArthur HIV dementia: an evolving disease , 2004, Journal of Neuroimmunology.

[2]  K. Marder,et al.  Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. , 2004, Archives of neurology.

[3]  C. Hall,et al.  Highly Active Antiretroviral Therapy Improves Neurocognitive Functioning , 2004, Journal of acquired immune deficiency syndromes.

[4]  J. McArthur,et al.  Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  A. d’Arminio Monforte,et al.  Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity , 2003, Neurology.

[6]  E. Masliah,et al.  Changing Patterns in the Neuropathogenesis of HIV During the HAART Era , 2003, Brain pathology.

[7]  C. Hinkin,et al.  Medication adherence among HIV+ adults , 2002, Neurology.

[8]  N. Sacktor The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. , 2002, Journal of neurovirology.

[9]  W. Schlote,et al.  HIV‐Related Neuropathology, 1985 to 1999: Rising Prevalence of HIV Encephalopathy in the Era of Highly Active Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.

[10]  P. Duca,et al.  Pathological findings in the central nervous system of AIDS patients on assumed antiretroviral therapeutic regimens: retrospective study of 1597 autopsies , 2002, AIDS.

[11]  A. Gamst,et al.  Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources , 2000, Neurology.

[12]  J. Becker,et al.  Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy , 1999, Neurology.

[13]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[14]  J. Beijnen,et al.  Antiretroviral drugs and the central nervous system. , 1998, AIDS.

[15]  J. McArthur,et al.  The reliability and validity of the subjective peripheral neuropathy screen. , 1998, The Journal of the Association of Nurses in AIDS Care : JANAC.

[16]  J. McArthur,et al.  Relationship between human immunodeficiency virus—associated dementia and viral load in cerebrospinal fluid and brain , 1997, Annals of neurology.

[17]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[18]  B. Brew,et al.  Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. , 1997, The Journal of infectious diseases.

[19]  D. Delis,et al.  Decline in working memory associated with HIV infection , 1995, Psychological Medicine.

[20]  J. Becker,et al.  Cognitive performance after progression to AIDS , 1995, Neurology.

[21]  R. Bornstein,et al.  Neuropsychological performance in symptomatic and asymptomatic HIV infection. , 1993, AIDS.

[22]  David A. Cooper,et al.  Changes in neuropsychological performance of AIDS‐related complex patients who progress to AIDS , 1992, AIDS.

[23]  E. Miller,et al.  Neuropsychological performance in HIV-1 immunocompromised patients: a preliminary report. , 1989, Journal of clinical and experimental neuropsychology.

[24]  J. Sidtis,et al.  Neuropsychological characterization of the AIDS dementia complex: a preliminary report. , 1988, AIDS.

[25]  M. Trimble,et al.  Neuropsychological and Behavioral Sequelae of Spontaneous Seizures , 1986, Annals of the New York Academy of Sciences.

[26]  F. Mott,et al.  Pathological Findings in the Central Nervous System of a Case of Myasthenia Gravis , 1924, Proceedings of the Royal Society of Medicine.

[27]  J. Barth,et al.  The Halstead-Reitan Neuropsychological Test Battery. , 2000 .

[28]  Eyton,et al.  A CONTROLLED TRIAL OF TWO NUCLEOSIDE ANALOGUES PLUS INDINAVIR IN PERSONS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND CD4 CELL COUNTS OF 200 PER CUBIC MILLIMETER OR LESS , 2000 .

[29]  D. Groothuis,et al.  The entry of antiviral and antiretroviral drugs into the central nervous system. , 1997, Journal of neurovirology.

[30]  R. Bornstein,et al.  Duration of illness and neuropsychological performance in asymptomatic HIV infection. , 1994, The Journal of neuropsychiatry and clinical neurosciences.

[31]  A. Saykin,et al.  Longitudinal evaluation of neuropsychological function in homosexual men with HIV infection: 18-month follow-up. , 1991, The Journal of neuropsychiatry and clinical neurosciences.